
Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Osteomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.
Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 6 respectively.
Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.
Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 6 respectively.
Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Adaptive Phage Therapeutics Inc
BioVinc LLC
ContraFect Corp
Debiopharm International SA
Integrated BioTherapeutics Inc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Nabriva Therapeutics Plc
Sonoran Biosciences Inc
Companies Mentioned
Adaptive Phage Therapeutics Inc
BioVinc LLC
ContraFect Corp
Debiopharm International SA
Integrated BioTherapeutics Inc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Nabriva Therapeutics Plc
Sonoran Biosciences Inc
Table of Contents
35 Pages
- Introduction
- Global Markets Direct Report Coverage
- Osteomyelitis - Overview
- Osteomyelitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Osteomyelitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteomyelitis - Companies Involved in Therapeutics Development
- Adaptive Phage Therapeutics Inc
- BioVinc LLC
- ContraFect Corp
- Debiopharm International SA
- Integrated BioTherapeutics Inc
- Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
- Nabriva Therapeutics Plc
- Sonoran Biosciences Inc
- Osteomyelitis - Drug Profiles
- (tobramycin + vancomycin SR) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- afabicin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologics for Diabetic Foot Osteomyelitis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BV-600022 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ceforanide - Drug Profile
- Product Description
- Mechanism Of Action
- CF-296 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lefamulin acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TPH-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Osteomyelitis - Dormant Projects
- Osteomyelitis - Product Development Milestones
- Featured News & Press Releases
- Jul 19, 2021: ContraFect announces multiple publications on CF-296 demonstrating potent in vivo antimicrobial activity
- Mar 10, 2021: Adaptive Phage Therapeutics announces FDA clearance of IND application for PhageBank in treatment of diabetic foot osteomyelitis
- Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors
- Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Osteomyelitis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Osteomyelitis - Pipeline by Adaptive Phage Therapeutics Inc, 2022
- Osteomyelitis - Pipeline by BioVinc LLC, 2022
- Osteomyelitis - Pipeline by ContraFect Corp, 2022
- Osteomyelitis - Pipeline by Debiopharm International SA, 2022
- Osteomyelitis - Pipeline by Integrated BioTherapeutics Inc, 2022
- Osteomyelitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2022
- Osteomyelitis - Pipeline by Nabriva Therapeutics Plc, 2022
- Osteomyelitis - Pipeline by Sonoran Biosciences Inc, 2022
- Osteomyelitis - Dormant Projects, 2022
- List of Figures
- Number of Products under Development for Osteomyelitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.